Jesse T Jacob1, Carlos A DiazGranados. 1. Division of Infectious Diseases, Emory University School of Medicine, Orr Building, Suite 1020, 550 Peachtree Street NE, Atlanta, GA 30308, USA. jtjacob@emory.edu
Abstract
BACKGROUND: Patients with methicillin-resistant Staphylococcus aureus (MRSA) infections caused by isolates with a high but 'susceptible' minimum inhibitory concentration (MIC) to vancomycin may suffer poor outcomes. The aim of this study was to determine the association of high compared to low vancomycin MICs and clinical outcomes (treatment failure and mortality) in patients with MRSA infections. METHODS: PubMed, the Cochrane Library, and electronic abstracts from meetings were queried from January 2000 to July 2010. Two reviewers independently screened titles and abstracts of studies evaluating outcomes of patients with MRSA infections, using broth microdilution (BMD) or the Etest to determine MIC, for full-text review. Patients participating in included studies were classified into two mutually exclusive groups: high MIC or low MIC. High MIC was defined as MIC ≥1mg/l by BMD or ≥1.5mg/l by Etest. Study-defined failure and mortality were assessed in each group. RESULTS: Fourteen publications and six electronic abstracts met the inclusion criteria, with 2439 patients (1492 high MIC and 947 low MIC). There was no evidence of publication bias or heterogeneity. An increased risk of failure was observed in the high MIC group compared to the low MIC group (summary risk ratio (RR) 1.40, 95% confidence interval (CI) 1.15-1.71). The overall mortality risk was greater in the high MIC group than in the low MIC group (summary RR 1.42, 95% CI 1.08-1.87). Sensitivity analyses showed similar findings for failure (summary RR 1.37, 95% CI 1.09-1.73) and mortality (summary RR 1.46, 95% CI 1.06-2.01) for patients with bacteremia. The study quality was poor-to-moderate, and study-defined endpoints were variable. CONCLUSIONS: A susceptible but high MIC to vancomycin is associated with increased mortality and treatment failure among patients with MRSA infections.
BACKGROUND:Patients with methicillin-resistant Staphylococcus aureus (MRSA) infections caused by isolates with a high but 'susceptible' minimum inhibitory concentration (MIC) to vancomycin may suffer poor outcomes. The aim of this study was to determine the association of high compared to low vancomycin MICs and clinical outcomes (treatment failure and mortality) in patients with MRSA infections. METHODS: PubMed, the Cochrane Library, and electronic abstracts from meetings were queried from January 2000 to July 2010. Two reviewers independently screened titles and abstracts of studies evaluating outcomes of patients with MRSA infections, using broth microdilution (BMD) or the Etest to determine MIC, for full-text review. Patients participating in included studies were classified into two mutually exclusive groups: high MIC or low MIC. High MIC was defined as MIC ≥1mg/l by BMD or ≥1.5mg/l by Etest. Study-defined failure and mortality were assessed in each group. RESULTS: Fourteen publications and six electronic abstracts met the inclusion criteria, with 2439 patients (1492 high MIC and 947 low MIC). There was no evidence of publication bias or heterogeneity. An increased risk of failure was observed in the high MIC group compared to the low MIC group (summary risk ratio (RR) 1.40, 95% confidence interval (CI) 1.15-1.71). The overall mortality risk was greater in the high MIC group than in the low MIC group (summary RR 1.42, 95% CI 1.08-1.87). Sensitivity analyses showed similar findings for failure (summary RR 1.37, 95% CI 1.09-1.73) and mortality (summary RR 1.46, 95% CI 1.06-2.01) for patients with bacteremia. The study quality was poor-to-moderate, and study-defined endpoints were variable. CONCLUSIONS: A susceptible but high MIC to vancomycin is associated with increased mortality and treatment failure among patients with MRSA infections.
Authors: Jeffrey C Hageman; Laura A Liedtke; Rebecca H Sunenshine; Larry J Strausbaugh; L Clifford McDonald; Fred C Tenover Journal: Clin Infect Dis Date: 2006-07-24 Impact factor: 9.079
Authors: Vance G Fowler; Helen W Boucher; G Ralph Corey; Elias Abrutyn; Adolf W Karchmer; Mark E Rupp; Donald P Levine; Henry F Chambers; Francis P Tally; Gloria A Vigliani; Christopher H Cabell; Arthur Stanley Link; Ignace DeMeyer; Scott G Filler; Marcus Zervos; Paul Cook; Jeffrey Parsonnet; Jack M Bernstein; Connie Savor Price; Graeme N Forrest; Gerd Fätkenheuer; Marcelo Gareca; Susan J Rehm; Hans Reinhardt Brodt; Alan Tice; Sara E Cosgrove Journal: N Engl J Med Date: 2006-08-17 Impact factor: 91.245
Authors: Dennis L Stevens; Daniel Herr; Harry Lampiris; John Lee Hunt; Donald H Batts; Barry Hafkin Journal: Clin Infect Dis Date: 2002-05-13 Impact factor: 9.079
Authors: Pamela A Moise-Broder; George Sakoulas; George M Eliopoulos; Jerome J Schentag; Alan Forrest; Robert C Moellering Journal: Clin Infect Dis Date: 2004-05-21 Impact factor: 9.079
Authors: Kimberly C Claeys; Evan J Zasowski; Anthony M Casapao; Abdalhamid M Lagnf; Jerod L Nagel; Cynthia T Nguyen; Jessica A Hallesy; Mathew T Compton; Keith S Kaye; Donald P Levine; Susan L Davis; Michael J Rybak Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191
Authors: R A Cetinkaya; S Yilmaz; A Ünlü; P Petrone; C Marini; E Karabulut; M Urkan; E Kaya; K Karabacak; M Uyanik; I Eker; A Kilic; A Gunal Journal: Eur J Trauma Emerg Surg Date: 2017-09-30 Impact factor: 3.693
Authors: R Falcón; E M Mateo; A Talaya; E Giménez; V Vinuesa; M Á Clari; D Navarro Journal: Eur J Clin Microbiol Infect Dis Date: 2017-07-25 Impact factor: 3.267
Authors: Young Kyung Yoon; Dae Won Park; Jang Wook Sohn; Hyo Youl Kim; Yeon-Sook Kim; Chang-Seop Lee; Mi Suk Lee; Seong-Yeol Ryu; Hee-Chang Jang; Young Ju Choi; Cheol-In Kang; Hee Jung Choi; Seung Soon Lee; Shin Woo Kim; Sang Il Kim; Eu Suk Kim; Jeong Yeon Kim; Kyung Sook Yang; Kyong Ran Peck; Min Ja Kim Journal: Antimicrob Agents Chemother Date: 2013-10-28 Impact factor: 5.191